Inclusion Criteria:

          -  Known diagnosis of neuroendocrine tumor or suspected SSTR positive tumors by
             111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen where clinically indicated

          -  At least 18 years of age

          -  Able to provide informed consent

          -  Karnofsky performance score greater than 50

          -  Females of childbearing potential must have a negative pregnancy test at
             screening/baseline

        Exclusion Criteria:

          -  Serum creatinine > 2.0 mg/dL

          -  Hepatic enzyme levels more than 3 times upper limit of normal

          -  Known severe allergy or hypersensitivity to IV radiographic contrast

          -  Use of any other investigational product or device within 30 days prior to dosing, or
             known requirement for any other investigational agent prior to completion of all
             scheduled study assessments

          -  Patients with a body weight of 400 pounds or more or not able to enter the bore of the
             PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT,
             and MRI that will result

          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,
             etc.)

          -  Inability to complete the needed investigational standard-of-care imaging examinations
             due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Recognized concurrent active infection

          -  Previous systemic or radiation treatment for another cancer of any type within the
             last 2 years

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance